It is now widely acknowledged that phosphatidylserine is a multifunctional bioactive lipid. In this review, we focus on the function of phosphatidylserine in modulating cholesterol metabolism, influencing inflammatory response and regulating coagulation system, and discuss promising phosphatidylserine-based therapeutic approaches and detection techniques in atherosclerosis.
INTRODUCTION
The increasing prevalence of cardiovascular disease has stimulated an active search for novel therapeutic agents. Atherosclerosis represents a pathological process underlying the development of cardiovascular disease, characterized by fat deposits and chronic inflammation of the vessel wall.
Phosphatidylserine provides an attractive target for treatment of atherosclerosis being a natural phospholipid with multiple anti-inflammatory functions, which is also involved in the regulation of hemostasis and coagulation.
In cell membranes, phosphatidylserine is normally located in the inner leaflet of lipid bilayer, with an exceptional surface exposure during a suicide phenomenon known as apoptosis. Interestingly, phosphatidylserine constitutes a minor component of the surface monolayer of HDL, suggesting that there may be a functional requirement for phosphatidylserine exposure in biological systems. It is important in this context that a potent anti-inflammatory functionality of phosphatidylserine-enriched reconstituted HDL has recently been reported [1] .
The review summarizes current knowledge in the emerging field of phosphatidylserine research and discusses possible functions of this lipid in the vascular biology and its implications for atherosclerosis. The roles of phosphatidylserine in the redistribution of plasma membrane cholesterol and HDL biogenesis will be discussed and antiinflammatory and thrombolytic mechanisms of phosphatidylserine effects on atherosclerotic vascular lesions reviewed. The last section describes new therapeutic and diagnostic approaches for atherosclerosis, which employ lipid-based cargos enriched with phosphatidylserine. hallmark of atherosclerosis. Molecular machinery of macrophages allows them to recognize and engulf modified apolipoprotein B-containing lipoproteins and apoptotic bodies, which both constitute two major sources of cholesterol in atherosclerotic plaques. However, because of the lack of the capacity to catabolize cholesterol, macrophages, as many other cells, express active ATP-binding cassette (ABC) cholesterol transporters, including ABCA1 and ABCG1, which enable export of the excess cholesterol to extracellular acceptors, primarily to apolipoprotein A-I (apoA-I) and HDL, in a process termed cellular cholesterol efflux. Maintenance of cholesterol homeostasis in macrophages is mediated by intracellular sterol sensory-dependent machinery, involving liver X receptors (LXR) which regulate the expression of ABC transporters on the cell surface. Recently, an existence of a novel membrane-initiated pathway has been demonstrated which results in a rapid ABCA1 upregulation [2 && ]. This pathway relies on the phosphatidylserinedependent recognition of apoptotic cells by the phosphatidylserine membrane receptor, brainspecific angiogenesis inhibitor 1, and subsequent intracellular signal for engulfment and cell motility 1/ras-related C3 botulinum toxin substrate 1 (Rac1) activation. Interestingly, this pathway is completely independent of the apoptotic body engulfment and, therefore, of the intracellular cholesterol sensing via the LXR pathway suggesting that phosphatidylserine-mediated recognition of apoptotic bodies by macrophages promotes an additional signaling pathway prior to cholesterol loading to ensure optimal cholesterol hemostasis via triggering ABCA1 expression ( Fig. 1) [2 && ]. ABCA1 and cholesterol efflux per se elicit anti-inflammatory effects by virtue of reducing cell membrane lipid raft and cholesterol content. Furthermore, it is now recognized that ABCA1, beyond its activity as a lipid transporter, acts as an anti-inflammatory receptor via interaction with apoA-I and subsequent activation of an anti-inflammatory signaling pathway involving Janus-activated kinase-2/signal transducer and activator of transcription 3, which counterbalances proinflammatory events associated with the activation of nuclear factor-kB pathway [3] . Moreover, interaction between ABCA1 and apoA-I results in the formation of HDL, which is well known as a potent anti-inflammatory lipoprotein. Taken together, phosphatidylserine-mediated recognition of apoptotic bodies that activate specific membrane-initiated signaling further links phosphatidylserine to cholesterol metabolism and lipid homeostasis [2 && ]. Cholesterol has been identified as a crucial component of lipid rafts. However, it remains unclear how cholesterol trafficking is regulated in signal transduction hubs located in lipid raft nanodomains. Recently, using a newly-developed cholesterol biosensor to visualize and monitor cellular cholesterol in cytosolic leaflets in a live-cell model, a link has been found between phosphatidylserine and cholesterol distribution within the lipid bilayer [4] . Using phosphatidylserine synthase mutated (PSB-2) cell line that displays very low phosphatidylserine synthase activities, reduction of phosphatidylserine content in the plasma membrane was shown to be associated with cholesterol redistribution from the inner to the exofacial leaflet of the plasma membrane [4] . Furthermore, in the lipid add-back experiments, phosphatidylserine supplementation largely restored cholesterol localization, whereas other phospholipids exhibited no effect. These data suggest that phosphatidylserine causes cholesterol retention in the inner leaflet of the plasma membrane, opening a therapeutic possibility to modulate proinflammatory signaling pathways via phosphatidylserine-mediated transbilayer distribution of cholesterol in lipid raft scaffold structures.
Consistent with these observations, it has recently been shown that depletion of phosphatidylserine in the inner leaflet of the plasma membrane occurs concomitantly with depletion of cholesterol upon incubation of canine kidney cells with b-cyclodextrin, a cholesterol-depleting agent. This phenomenon was accompanied by a disruption in the organization of cholesterol and phosphatidylserine, both remaining in the inner leaflet of the plasma membrane [5] . Although it is not yet determined how phosphatidylserine and cholesterol influence each other's trafficking or retention, it is of note that both are synthesized in the endoplasmic
KEY POINTS
Phosphatidylserine of endothelial cells, leukocytes, platelets, and lipid-based cargos can play important roles in atherosclerosis via resolving inflammation, expanding B1a lymphocytes, enhancing cellular cholesterol efflux capacity, inducing efferocytosis of apoptotic cells, and modulating thrombolysis.
These biological activities of phosphatidylserine are linked to intracellular signaling events stimulated directly by binding of the phosphatidylserine molecule to its receptors.
Clinical applications of phosphatidylserine may include design of novel therapeutic agents, primarily reconstituted HDL, and lipid-based drug delivery systems.
reticulum and enriched in the plasma membrane and recycling endosomes. Electrical charges resulting from the asymmetric distribution of phosphatidylserine and cholesterol can be involved in the control of vesiculation and subsequent trafficking [5] .
Other mechanisms, including nonvesicular transport by lipid-transfer proteins, have been identified as important pathways to enrich the plasma membrane in phosphatidylserine and cholesterol [6, 7] . In this context, the question remains as to whether phosphatidylserine, in addition to influencing 'within-membrane' cholesterol movement, is also involved in 'betweenmembrane' cholesterol trafficking. Enigmatically, asymmetric enrichment of phosphatidylserine in Phosphatidylserine distribution in cellular membranes is tightly regulated. Phosphatidylserine cosegregates with cholesterol in the inner leaflet of plasma membranes. In turn, phosphatidylserine-mediated transbilayer distribution of cholesterol affects lipid raft-mediated signaling, membrane localization of signaling complexes, including K-Ras, and cholesterol availability for HDL formation and HDL-mediated cellular lipid efflux. Activation of engulfment and cell motility 1 (ELMO1)/Rac1 signaling pathway via the phosphatidylserine membrane receptor brain-specific angiogenesis inhibitor 1 (BAI1) leads to a rapid ABCA1 upregulation in macrophages. The increase in ABCA1 not only promotes cholesterol efflux but also activates an anti-inflammatory signaling pathway via Janus-activated kinase-2 (JAK2)/signal transducer and activator of transcription 3 (STAT3). Phosphatidylserine-containing liposomes expedite expansion of B1a cells, secreting polyreactive IgM antibodies in a T-cell immunoglobulin mucin (TIM) type 1 (TIM-1) receptor-dependent manner. The liposomes can also activate phagocytes through TIM-4 receptor, promoting efferocytosis of apoptotic bodies. Phosphatidylserine externalization in endothelial cells and peripheral blood leukocytes can promote thrombus formation by factor Xa binding, whereas activating local fibrinolysis via binding plasminogen at the surface of platelet plasma membranes within the microenvironment of the thrombus, consistent with a dual regulatory role of phosphatidylserine in hemostasis.
plasma membranes as compared with endoplasmic reticulum, where phosphatidylserine is synthesized, was shown to be regulated by members of the lipid transport family, known as oxysterol-binding protein. Initially, these lipid-transfer proteins were found to be essential for establishing asymmetric distribution of cholesterol in Golgi versus endoplasmic reticulum membranes. Another oxysterol-binding protein subfamily involved in the lipid exchange machinery has been shown to drive asymmetric phosphatidylserine trafficking to plasma membranes [6, 8] . Therefore, it is also possible that 'between-membrane' transport of cholesterol is to some degree associated with phosphatidylserine trafficking.
Functional properties of plasma membranes are affected by modifications of their lipid composition. To date, little is known about the spatial array of membrane lipids and their potential to regulate receptor-mediated signaling. A recent study, using a direct lipid visualization method, has elegantly shown a causative association between inner plasma membrane content of phosphatidylserine and mislocalization of V-Ki-ras2 Kirsten rat sarcoma (K-Ras), a member of GTP-binding proteins (RasGTPase) superfamily, which plays a crucial role in many signal transduction pathways [5] . Detailed analysis of metabolic consequences associated with inhibition of acid sphingomyelinase, using its pharmacological inhibitor fendiline, reveal that the perturbation of the sphingomyelin-to-ceramide ratio was mechanistically associated with reduced phosphatidylserine and cholesterol content in the inner leaflet of the plasma membrane; such lipid depletion was directly responsible for the mislocalization of K-Ras isoforms. Furthermore, lipid add-back experiments revealed that there might have been distinct phosphatidylserine operational pool in the plasma membrane, consistent with the fact that supplementation of exogenous phosphatidylserine rapidly restored K-Ras assembly in the plasma membrane. However, addition of exogenous cholesterol only restored nanoclustering of one of the K-Ras isoforms, indicating the existence of a phosphatidylserine-dependent cholesterol pool that plays a key role in preserving cholesterol-dependent K-Ras nanoclustering in the plasma membrane. In accordance with these data, an extensive K-Ras mislocalization has been identified in fibroblast plasma membranes in patients with Niemann-Pick disease whose acid sphingomyelinase is completely or partially inactivated [5] . Thus, phosphatidylserine content in the plasma membrane contributes to K-Ras signaling by promoting plasma membrane binding and nanoclustering [5] .
PHOSPHATIDYLSERINE AND INFLAMMATION
It is well known that phosphatidylserine-mediated recognition of apoptotic bodies represents an important phagocytic response that operates by reprogramming macrophages to secrete anti-inflammatory mediators such as interleukin (IL) IL-10 and transforming growth factor-b [9, 10] . Given the crucial role of phosphatidylserine in the apoptotic machinery, phosphatidylserine-containing liposomes have been used as a strategy to mimic inflammation-resolving properties of apoptotic cells to resolve and to ultimately extinguish inflammation. The results of these approaches have revealed several mechanisms which contribute to beneficial effects of phosphatidylserine-containing liposomes in suppressing inflammation, suggesting the potential of targeting macrophage-driven resolution mechanisms to attenuate atherogenesis [11] [12] [13] [14] [15] [16] .
More than 10 different receptors and bridging molecules participate in the cellular phosphatidylserine sensing, and this complexity is expanded further by associated intracellular signaling machinery. Recent functional studies have identified a class of phosphatidylserine receptors that is essential for anti-inflammatory effects of phosphatidylserine As an active metabolite of phosphatidylserine, lysophosphatidylserine is often considered as a proinflammatory agent, whose production is tightly regulated in healthy, but not in inflammatory, cells. However, lysophosphatidylserine can act as an antiinflammatory and proresolving mediator in activated neutrophils by signaling aimed at rapid phagocytic removal of recruited neutrophils through the activation of macrophages. These findings provide further insight into potential therapeutic strategies based on the regulation of phosphatidylserine metabolism depending on the cell type and underlying signaling network in inflammatory diseases [19] .
PHOSPHATIDYLSERINE AND COAGULATION
Chronic inflammatory diseases, including atherosclerosis, are associated with a hypercoagulable and prothrombotic state. It is important in this regard that phosphatidylserine is widely accepted to act as a key regulator of hemostasis and thrombosis [20] . Recently, it has been found that upon incubation of endothelial cells with uremic milieu, a characteristic of chronic kidney disease, the cells start to expose phosphatidylserine at the surface and form microparticles which are enriched with phosphatidylserine on their surfaces [21] . Although it is not yet determined which specific components of uremic toxins account for a cross-talk between endothelial cells, kidney dysfunction, and increased phosphatidylserine exposure, in-vitro experiments reveal that phosphatidylserine externalization in endothelial cells and peripheral blood leukocytes provides binding sites for factor Xa and prothrombinase complexes and thereby facilitates thrombus formation [21, 22] . Importantly, shear stress has recently been discovered to induce phosphatidylserine expression on the surface of platelet plasma membranes within the microenvironment of the thrombus in a process that enhances plasminogen binding and subsequent local fibrinolysis [23 && ]. This anticoagulant pathway contrasts with the procoagulant role of phosphatidylserine externalization in endothelial cells and peripheral blood leukocytes. It appears therefore that phosphatidylserine plays a role in maintaining a balance between pro and anticoagulant pathways during coagulation and hemostasis. Moreover, these interesting findings suggest the importance of phosphatidylserine-exposing platelets as a potential target for novel thrombolytic therapies in human atherosclerotic lesions (Fig. 1) .
OUTLOOK

Therapeutic perspectives of phosphatidylserine in atherosclerosis
Using phosphatidylserine as a therapeutic agent goes back to the association of phosphatidylserine supplementation with cognitive function and memory improvement in patients with Alzheimer's disease in the late 1980s [24] . Although there is no consensus regarding the potential of phosphatidylserine supplementation in Alzheimer's disease, new information on neuroprotective functions of phosphatidylserine has been recently published [25, 26] .
Lipid vesicles, such as synthetic liposomes or microvesicles, are emerging therapeutic platforms for targeted delivery of multicomponent cargos. The design of an efficacious lipid vesicle composition remains a major challenge for these approaches. It is important in this regard that phosphatidylserine has been shown to represent an essential component for the microvesicles internalization into endothelial cells [27] . Using monoclonal antibodies, phosphatidylserine receptor was identified as a specific cellsurface interacting partner for such internalization processes [27] . Despite the fact that the effects of the microvesicle or liposome-associated phosphatidylserine on vascular biology remain to be investigated, it is conceivable that the presence of phosphatidylserine on the surface of therapeutic lipid cargos can enhance endothelial uptake and consequently improve cellular delivery and efficacy.
For instance, a monoclonal antibody against phosphatidylserine has gained attention as a therapeutic strategy by targeting immunosuppressive functions mediated by this lipid [28] . Intriguingly, increased phosphatidylserine content in tumor endothelial cells can potentially enable them to escape host immune cells through a mechanism similar to that known for apoptotic bodies, which includes shutting down the production of proinflammatory cytokines such as TNF-a and IL-1b, or upregulating synthesis of anti-inflammatory cytokines, such as IL-10 and transforming growth factor-b. Recently, a phosphatidylserine-targeting antibody has been successfully passed through a phase 2 clinical trial in lung cancer, highlighting the potential of phosphatidylserine as a target for pharmacological intervention in this disorder.
Size, shape, and composition of therapeutic cargos may also affect subsequent signaling events through altered interactions with cell surface receptors. This phenomenon has been particularly evidenced through immune tolerance mediated by rod-shaped poly D,L-lactide-co-glycolide (PLGA) nanoparticles [29 & ]. Enhanced anti-inflammatory and effector T-cell dampening effects of phosphatidylserine-loaded nanorod versus liposomal phosphatidylserine observed using this strategy suggested that the geometry of phosphatidylserine presentation itself can determine the signaling efficacy of phosphatidylserine-containing particles [29 & ]. Together, these promising data highlight the therapeutic potential of phosphatidylserine; however their relevance to atherosclerosis still remains to be established.
Phosphatidylserine and HDL functionality
HDL can be considered as an essential protective system against development of vascular atherosclerotic lesions. The key to understanding the role of HDL in vascular biology includes the elucidation of biomolecules participating in the formation, remodeling, and functioning of HDL. In this context, substantial compositional variations within HDL subpopulations under normal and pathological metabolic conditions have been reported, and specific roles for phospholipids and bioactive lipids carried by HDL have been proposed [1, 30, 31] .
In view of the role of phosphatidylserine in the control of multiple biological processes, including cholesterol metabolism and inflammatory immune responses, it is of interest to study the putative role of phosphatidylserine as a constituent of HDL in the process of vascular homeostasis and repair. Recent studies have indicated that phosphatidylserine is enriched in small, dense HDL particles, which display potent antiatherosclerotic activities [32] . Furthermore, enrichment of reconstituted HDL with phosphatidylserine significantly enhanced antiatherogenic functionality of the lipoprotein [1] .
It can be speculated that phosphatidylserine in HDL contributes to HDL-receptor interactions. Phosphatidylserine also appears to accelerate HDL assembly and cholesterol loading by reducing microenvironmental pH and creating highly curved interfaces at the edge of nascent discoidal HDL [33] . It is tempting to propose that selective enrichment of phosphatidylserine in specific HDL subpopulations can contribute to improved HDL remodeling and enhanced functionality [34 & ].
Diagnostic applications of phosphatidylserine for atherosclerosis
Numerous studies have characterized phenotypes and subsets of human macrophages under proatherosclerotic conditions in vitro [35] ; much less work has, however, been devoted to studies of macrophages in atherosclerotic lesions in vivo. Labeled phosphatidylserine-containing liposomes have recently been developed for in-vivo macrophage imaging in atheromas [36
&&
]. Development of noninvasive imaging of atherosclerotic burden and inflammation using liposome-based approaches will, however, require a better understanding of macrophage biology and is still in its early phase.
CONCLUSION
Present data reveal that surface phosphatidylserine is required for the regulation of cholesterol metabolism, inflammation, and hemostasis. Phosphatidylserine acts as a ligand for specific interactions with endothelial cells, leukocytes, platelets, and lipid-based cargos, modulating functional responses in target cells. All these functions are of a primary importance in the physiology of vascular system and pathogenesis of vascular dysfunction in atherosclerosis ( Fig. 1) . As a consequence, phosphatidylserine-containing cargos possess a capacity to improve diagnosis and treatment of atherosclerosis, providing directions for future research.
